Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-19 21:57 | 2026-03-17 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | SELL | $32.14 | 8,895 | $285,901 | 28,836 |
| 2026-03-19 21:58 | 2026-03-17 | STOK | Stoke Therapeutics, Inc. | Hoitt Jason | Officer | SELL | $32.14 | 3,712 | $119,311 | 10,276 |
| 2026-03-19 22:00 | 2026-03-17 | STOK | Stoke Therapeutics, Inc. | Leggett Thomas | Officer | SELL | $32.14 | 4,578 | $147,145 | 10,172 |
| 2026-03-19 22:01 | 2026-03-17 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | OPT+S | $31.92 | 14,311 | $456,836 | 40,702 |
| 2026-03-19 21:43 | 2026-03-17 | PCRX | Pacira BioSciences, Inc. | Froimson Mark | Director | SELL | $21.81 | 500 | $10,905 | 20,136 |
| 2026-03-19 21:43 | 2026-03-17 | PCRX | Pacira BioSciences, Inc. | SLONIN JONATHAN | Officer | SELL | $22.82 | 3,261 | $74,416 | 223,640 |
| 2026-03-19 21:29 | 2026-03-18 | ALDX | Aldeyra Therapeutics, Inc. | Alfieri Michael | Officer | BUY | $1.42 | 5,000 | $7,100 | 7,500 |
| 2026-03-19 21:07 | 2026-03-17 | CORT | CORCEPT THERAPEUTICS INC | BAKER G LEONARD JR | Director | BUY | $33.14 | 100,000 | $3,313,810 | 1,146,631 |
| 2026-03-19 20:30 | 2026-03-19 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $529.95 | 8,300 | $4,398,611 | 45,172 |
| 2026-03-19 20:30 | 2026-03-18 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $529.59 | 9,500 | $5,031,117 | 40,513 |
| 2026-03-19 20:01 | 2026-03-17 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Sabag Mark | Officer | SELL | $30.14 | 62,102 | $1,871,816 | 224,940 |
| 2026-03-18 21:13 | 2026-03-16 | CRNX | Crinetics Pharmaceuticals, Inc. | Knight Jeff E. | Officer | SELL | $37.37 | 9,911 | $370,412 | 112,018 |
| 2026-03-18 21:11 | 2026-03-16 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Officer | SELL | $37.37 | 10,612 | $396,611 | 137,101 |
| 2026-03-18 21:05 | 2026-03-16 | CRNX | Crinetics Pharmaceuticals, Inc. | Struthers Richard Scott | Director, Officer | SELL | $37.37 | 21,981 | $821,513 | 404,778 |
| 2026-03-18 20:07 | 2026-03-16 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer | OPT+S | $16.15 | 25,492 | $411,607 | 3,622 |
| 2026-03-18 21:03 | 2026-03-18 | TNXP | Tonix Pharmaceuticals Holding Corp. | LEDERMAN SETH | Director, Officer | BUY | $14.89 | 15,000 | $223,350 | 15,001 |
| 2026-03-18 21:18 | 2026-03-16 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Bhatt Padmanabh P. | Officer | OPT+S | $50.24 | 107,250 | $5,388,433 | 17,044 |
| 2026-03-18 20:05 | 2026-03-16 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | OPT+S | $28.09 | 10,000 | $280,861 | 105,211 |
| 2026-03-18 21:19 | 2026-03-16 | IONS | IONIS PHARMACEUTICALS INC | HOUGEN ELIZABETH L | Officer | OPT+S | $72.43 | 225,220 | $16,313,676 | 82,660 |
| 2026-03-18 21:37 | 2026-03-17 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $62.15 | 36,601 | $2,274,752 | 430,330 |
| 2026-03-19 00:00 | 2026-03-17 | EOLS | Evolus, Inc. | Avelar Rui | Officer | OPT+S | $4.89 | 29,996 | $146,629 | 430,542 |
| 2026-03-19 00:00 | 2026-03-17 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | OPT+S | $4.89 | 116,720 | $570,562 | 618,369 |
| 2026-03-18 22:43 | 2026-03-16 | CNTA | Centessa Pharmaceuticals plc | Anderson Karen M. | Officer | OPT+S | $28.19 | 74,811 | $2,109,176 | 62,085 |
| 2026-03-18 22:23 | 2026-03-16 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Director | SELL | $28.68 | 41,861 | $1,200,573 | 15,804 |
| 2026-03-18 22:12 | 2026-03-16 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | Officer | SELL | $13.96 | 31,067 | $433,636 | 232,699 |
| 2026-03-18 21:40 | 2026-03-17 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | SELL | $62.15 | 12,033 | $747,851 | 153,902 |
| 2026-03-18 21:43 | 2026-03-17 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $62.15 | 8,542 | $530,885 | 71,573 |
| 2026-03-18 21:46 | 2026-03-17 | CYTK | CYTOKINETICS INC | Lee Sung | Officer | SELL | $62.15 | 4,935 | $306,710 | 87,127 |
| 2026-03-18 20:42 | 2026-03-16 | ARDX | ARDELYX, INC. | RAAB MICHAEL | Director, Officer | OPT+S | $5.84 | 41,666 | $243,329 | 1,816,448 |
| 2026-03-18 20:55 | 2026-03-18 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $62.07 | 1,930 | $119,795 | 78,185 |
| 2026-03-18 20:30 | 2026-03-16 | LFVN | Lifevantage Corp | Lewis Darwin | Director | BUY | $5.23 | 1,055 | $5,518 | 136,563 |
| 2026-03-18 20:33 | 2026-03-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $536.75 | 9,500 | $5,099,104 | 40,513 |
| 2026-03-18 20:09 | 2026-03-16 | IRD | Opus Genetics, Inc. | Jayagopal Ashwath | Officer | SELL | $5.12 | 3,719 | $19,046 | 516,775 |
| 2026-03-18 20:10 | 2026-03-16 | IRD | Opus Genetics, Inc. | Magrath George | Director, Officer | SELL | $5.21 | 24,438 | $127,327 | 1,750,855 |
| 2026-03-18 20:11 | 2026-03-16 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Officer | SELL | $5.25 | 2,816 | $14,770 | 190,312 |
| 2026-03-18 20:12 | 2026-03-16 | IRD | Opus Genetics, Inc. | SCHACHLE JOSEPH K | Officer | SELL | $5.25 | 3,719 | $19,525 | 300,781 |
| 2026-03-18 20:12 | 2026-03-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $2.71 | 6,424 | $17,377 | 713,602 |
| 2026-03-18 20:13 | 2026-03-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Director, Officer | SELL | $2.72 | 25,578 | $69,547 | 2,172,699 |
| 2026-03-18 20:13 | 2026-03-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $2.70 | 5,708 | $15,429 | 679,348 |
| 2026-03-17 21:02 | 2026-03-16 | UPB | Upstream Bio, Inc. | Deykin Aaron | Officer | SELL | $9.29 | 894 | $8,305 | 32,687 |
| 2026-03-17 21:00 | 2026-03-16 | UPB | Upstream Bio, Inc. | Ambrose Allison | Officer | SELL | $9.29 | 475 | $4,413 | 16,525 |
| 2026-03-17 20:59 | 2026-03-16 | UPB | Upstream Bio, Inc. | Houghton Adam | Officer | SELL | $9.29 | 699 | $6,494 | 24,301 |
| 2026-03-17 21:00 | 2026-03-16 | UPB | Upstream Bio, Inc. | Sutherland Everett Rand | Director, Officer | SELL | $9.29 | 2,093 | $19,444 | 72,907 |
| 2026-03-17 20:31 | 2026-03-13 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | SELL | $36.30 | 35,365 | $1,283,834 | 174,473 |
| 2026-03-17 20:30 | 2026-03-13 | LQDA | Liquidia Corp | Krepp Sarah | Officer | SELL | $38.00 | 16,261 | $617,918 | 148,397 |
| 2026-03-17 20:04 | 2026-03-13 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $481.79 | 2,329 | $1,122,089 | 35,405 |
| 2026-03-17 20:06 | 2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $40.91 | 7,641 | $312,560 | 33,377 |
| 2026-03-17 20:30 | 2026-03-13 | LQDA | Liquidia Corp | SINGH RAMAN | Director | OPT+S | $36.04 | 20,000 | $720,828 | 38,755 |
| 2026-03-17 21:44 | 2026-02-17 | DRMA | Dermata Therapeutics, Inc. | Bedoya-Toro Munera Maria E | Officer | BUY | $1.27 | 1,000 | $1,270 | 1,012 |
| 2026-03-17 21:11 | 2026-03-13 | NATR | NATURES SUNSHINE PRODUCTS INC | Yates Bryant J | Officer | SELL | $24.35 | 19,516 | $475,215 | 85,154 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.